Ex vivo identification, isolation and analysis of tumor-cytolytic T cells

Nature Medicine

Volumn 9, Issue 11, 2003, Pages 1377-1382

  Rubio, Valerie ^a   Stuge, Tor B ^a   Singh, Naileshni ^a   Betts, Michael R ^b   Weber, Jeffrey S ^c   Roederer, Mario ^b   Lee, Peter P ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CANCER VACCINE; GLYCOPROTEIN GP 100; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MELAN A; MEMBRANE PROTEIN; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL GRANULE; CELL ISOLATION; CELL LEVEL; CELL VIABILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; PRIORITY JOURNAL; TUMOR CELL DESTRUCTION; VACCINATION;

ANTIGENS, CD; HUMANS; LYSOSOMAL-ASSOCIATED MEMBRANE PROTEIN 1; LYSOSOME-ASSOCIATED MEMBRANE GLYCOPROTEINS; NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0345276633     PISSN: 10788956     EISSN: None     Source Type: Journal    
DOI: 10.1038/nm942     Document Type: Article

References (26)

1. Altman, J.D. et al. Phenotypic analysis of antigen-specific T lymphocytes. Science 274, 94-96 (1996).
2. Lee, P.P. et al. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat. Med. 5, 677-685 (1999).
3. Lee, P. et al. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19, 3836-3847 (2001).
4. Weber, J. et al. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected stage II melanoma. Cancer 97, 186-200 (2003).
5. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99, 16168-16173 (2002).
6. Molldrem, J.J. et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest. 111, 639-647 (2003).
7. Oh, S. et al. Selective induction of high avidity CTL by altering the balance of signals from APC. J. Immunol. 170, 2523-2530 (2003).
8. Dutoit, V. et al. Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR. J. Immunol. 168, 1167-1171 (2002).
9. Echchakir, H. et al. Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution. Proc. Natl. Acad. Sci. USA 99, 9358-9363 (2002).
10. O'Connor, D.H. et al. Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat. Med. 8, 493-499 (2002).
11. Cawthon, A.G. & Alexander-Miller, M.A. Optimal colocalization of TCR and CD8 as a novel mechanism for the control of functional avidity. J. Immunol. 169, 3492-3498 (2002).
12. Slifka, M.K. & Whitton, J.L. Functional avidity maturation of CD8(+) T cells without selection of higher affinity TCR. Nat. Immunol. 2, 711-717 (2001).
13. Margulies, D.H. TCR avidity: it's not how strong you make it, it's how you make it strong. Nat. Immunol. 2, 669-670 (2001).
14. Yee, C., Savage, P.A., Lee, P.P., Davis, M.M. & Greenberg, P.D. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162, 2227-2234 (1999).
15. Crawford, F., Kozono, H., White, J., Marrack, P. & Kappler, J. Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes. Immunity 8, 675-682 (1998).
16. Derby, M.A., Wang, J., Margulies, D.H. & Berzofsky, J.A. Two intermediate-avidity cytotoxic T lymphocyte clones with a disparity between functional avidity and MHC tetramer staining. Int. Immunol. 13, 817-824 (2001).
17. Dutoit, V., Guillaume, P., Cerottini, J.C., Romero, P. & Valmori, D. Dissecting TCR-MHC/peptide complex interactions with A2/peptide multimers incorporating tumor antigen peptide variants: crucial role of interaction kinetics on functional outcomes. Eur. J. Immunol. 32, 3285-3293 (2002).
18. + T cells by a flow cytometric assay for degranulation. J. Immunol. Methods (in the press).
19. Whiteside, T.L. et al. Enzyme-linked immunospot, cytokine flow cytometry, and tetramers in the detection of T-cell responses to a dendritic cell-based multipeptide vaccine in patients with melanoma. Clin. Cancer Res. 9, 641-649 (2003).
20. Snyder, J.E. et al. Measuring the frequency of mouse and human cytotoxic T cells by the Lysispot assay: independent regulation of cytokine secretion and short-term killing. Nat. Med. 9, 231-236 (2003).
21. Tomaru, U. et al. Detection of virus-specific T cells and CD8(+) T-cell epitopes by acquisition of peptide-HLA-GFP complexes: analysis of T-cell phenotype and function in chronic viral infections. Nat. Med. 9, 469-476 (2003).
22. + T cells specific to a single viral epitope. J. Immunol. 165, 6214-6220 (2000).
23. Bachmann, M.F., Barner, M., Viola, A. & Kopf, M. Distinct kinetics of cytokine production and cytolysis in effector and memory T cells after viral infection. Eur. J. Immunol. 29, 291-299 (1999).
24. Dudley, M.E. et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25, 243-251 (2002).
25. Khong, H.T. & Restifo, N.P. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3, 999-1005 (2002).
26. Dunn, G.P., Bruce, A.T., Ikeda, H., Old, L.J. & Schreiber, R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat. Immunol. 3, 991-998 (2002).